Bedside Anticoagulant Testing

Jacqueline Saw, David J. Moliterno

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Anticoagulants are central in the management of both atherothrombotic arterial and venous disorders. Unfractionated heparin (UFH) is currently the most widely used intravenous anticoagulant, but its dominance is progressively being supplanted by low molecularweight heparins (LMWH) and direct thrombin inhibitors. Nevertheless, at this juncture, the prevalence of UFH use necessitates knowledge of monitoring its anticoagulant effect, especially in the setting where high doses are required for therapeutic efficacy. Unfortunately, UFH has a relatively narrow therapeutic window, thus setting the premise for the monitoring of anticoagulant activity to optimize efficacy while maintaining safety. In this chapter, we will specifically review the role of bedside anticoagulant monitoring devices of antithrombin activity. There is considerably less need for routine anticoagulant monitoring of LMWH and direct thrombin inhibitors, given their more favorable pharmacokinetics; these will be briefly discussed as well.

Original languageEnglish
Title of host publicationAcute Coronary Syndromes, Third Edition
Subtitle of host publicationRevised and Expanded
Pages457-479
Number of pages23
ISBN (Electronic)9780203025673
DOIs
StatePublished - Jan 1 2004

Bibliographical note

Publisher Copyright:
© 2004 by Taylor & Francis Group, LLC.

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Bedside Anticoagulant Testing'. Together they form a unique fingerprint.

Cite this